These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18328009)

  • 1. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
    Hoffman S; Morrow KM; Mantell JE; Rosen RK; Carballo-Diéguez A; Gai F
    Arch Sex Behav; 2010 Jun; 39(3):748-60. PubMed ID: 19636696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
    Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
    AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
    Morrow K; Rosen R; Richter L; Emans A; Forbes A; Day J; Morar N; Maslankowski L; Profy AT; Kelly C; Abdool Karim SS; Mayer KH
    J Womens Health (Larchmt); 2003 Sep; 12(7):655-66. PubMed ID: 14583106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).
    Carballo-Diéguez A; Balán IC; Morrow K; Rosen R; Mantell JE; Gai F; Hoffman S; Maslankowski L; El-Sadr W; Mayer K
    AIDS Care; 2007 Sep; 19(8):1026-31. PubMed ID: 17852000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico.
    Giguere R; Carballo-Diéguez A; Ventuneac A; Mabragaña M; Dolezal C; Chen BA; Kahn JA; Zimet GD; McGowan I
    Cult Health Sex; 2012; 14(2):151-66. PubMed ID: 22084840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
    Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
    AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
    Baxter C; Yende-Zuma N; Tshabalala P; Abdool Karim Q; Abdool Karim SS
    Antiviral Res; 2013 Sep; 99(3):405-8. PubMed ID: 23832086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
    Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
    Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
    Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
    Trials; 2011 Mar; 12():67. PubMed ID: 21385354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
    Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
    Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG; Lanham M; Wilcher R; Gafos M; Karim QA; Heise L
    J Int AIDS Soc; 2015; 18(1):20536. PubMed ID: 26700845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
    Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
    Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.
    Abdulai MA; Baiden F; Adjei G; Afari-Asiedu S; Adjei K; Tawiah C; Newton S
    BMC Womens Health; 2012 Nov; 12():40. PubMed ID: 23114222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
    AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
    Jones HE; Chaikummao S; van de Wijgert JH; Friedland BA; Manopaiboon C; Witwatwongwana P; Wankrairot M; Chantharojwong N; Kilmarx PH
    J Womens Health (Larchmt); 2009 Jul; 18(7):1003-10. PubMed ID: 19575689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.